Immune Sensitive Tumor clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.

    San Francisco, California and other locations

Our lead scientists for Immune Sensitive Tumor research studies include .

Last updated: